Puma Biotechnology (PBYI) Projected to Release Quarterly Earnings on Thursday

Posted by on Aug 4th, 2026

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Puma Biotechnology to announce earnings of $0.04 per share and revenue of $53.00 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. Puma Biotechnology had a net margin of 10.69% and a return on equity of 20.30%. The company had revenue of $44.81 million for the quarter, compared to analysts’ expectations of $42.00 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Stock Down 3.0%

PBYI opened at $7.69 on Tuesday. Puma Biotechnology has a 12 month low of $3.04 and a 12 month high of $8.75. The company has a fifty day simple moving average of $7.72 and a 200 day simple moving average of $7.13. The stock has a market cap of $391.42 million, a P/E ratio of 16.02 and a beta of 1.22.

Insider Buying and Selling

In related news, CEO Alan H. Auerbach sold 44,058 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $363,919.08. Following the sale, the chief executive officer directly owned 7,261,671 shares in the company, valued at $59,981,402.46. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Allison Dorval sold 11,610 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $83,592.00. Following the completion of the sale, the director directly owned 90,780 shares in the company, valued at $653,616. This represents a 11.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 132,028 shares of company stock valued at $1,006,711. 22.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Puma Biotechnology

A number of large investors have recently added to or reduced their stakes in PBYI. Russell Investments Group Ltd. grew its stake in shares of Puma Biotechnology by 4,823,365.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after acquiring an additional 964,673 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Puma Biotechnology by 238.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 793,962 shares of the biopharmaceutical company’s stock valued at $4,724,000 after purchasing an additional 559,345 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Puma Biotechnology by 410.1% in the fourth quarter. AQR Capital Management LLC now owns 666,605 shares of the biopharmaceutical company’s stock valued at $3,966,000 after purchasing an additional 535,933 shares during the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Puma Biotechnology by 78.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 773,485 shares of the biopharmaceutical company’s stock worth $4,602,000 after purchasing an additional 339,924 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its position in shares of Puma Biotechnology by 35.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock worth $6,666,000 after purchasing an additional 292,108 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Weiss Ratings cut Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Puma Biotechnology currently has an average rating of “Hold”.

Get Our Latest Stock Report on Puma Biotechnology

About Puma Biotechnology

(Get Free Report)

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.

Featured Stories

Earnings History for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.